about
Evidence for the prevention and treatment of stroke in dialysis patientsFirst United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney diseaseAnalyses of cancer data from three ezetimibe trials.Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP)Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysisPrediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort studyThe effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.Effects of extended-release niacin with laropiprant in high-risk patients.Serum free light chains and the risk of ESRD and death in CKDStatin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials.Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials.Lipids in chronic kidney disease.Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.Randomized clinical trials--removing unnecessary obstacles.Randomized clinical trials--removing obstacles.A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease.Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study.The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.Increasing the use of mobile technology-derived endpoints in clinical trials.A practical method of measuring glomerular filtration rate by iohexol clearance using dried capillary blood spots.Testing the practical aspects of therapeutics by objective structured clinical examination.Dual blockade of the renin-angiotensin system: are two better than one?Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older menUse of gel-based separator tubes to stabilise phosphate in mailed blood samplesReassuring results with regard to the effect of donor nephrectomy on cardiovascular outcomesCommentary: Controversies in NICE guidance on chronic kidney diseaseCross-Sectional Analysis of Abnormalities of Mineral Homeostasis, Vitamin D and Parathyroid Hormone in a Cohort of Pre-Dialysis PatientsWhich cardiovascular risk factors matter in chronic kidney disease?Renal function: an emerging risk factor for cardiovascular disease?A pilot study of streptokinase-induced endothelial injury and platelet activation following acute myocardial infarctionAssociation between elevated plasma fibrinogen and the small, dense low-density lipoprotein phenotype among postmenopausal womenOxidative stress after thrombolysisThe Magic of Randomization versus the Myth of Real-World Evidence
P50
Q27023274-5D972782-8D54-4E9B-8F5B-D5E6A91D8937Q28218706-C1B00249-5D5B-49CD-BF9B-6A9189194DFBQ33365863-1C4A4021-53A2-4488-875E-931338F62E9CQ33797539-5F9DD12A-C0CB-4B1B-B111-2C06FC3B436BQ34062290-EF3A358B-F20F-46DA-B000-CEE744A90D1FQ34349235-03EA1484-739F-4E9D-885A-11EE10C7CE80Q34630074-DD58DF16-5975-41EC-B959-E46C552EE5A9Q35205560-F69DFDCF-8138-4C27-A29E-45C798493F2DQ35664565-94C7866B-E4B3-4417-9AC7-0727D2A5172BQ35917976-5849FBBF-A2E9-4BC8-88D9-4B47C5EFD23AQ36996668-49E0872E-EDB4-4DE7-98D3-CCFAC8C551C6Q37768502-F984C20E-B414-42E5-B6EB-05C98EC63312Q41931102-CBB510C7-AABF-4C07-AA39-D1A9C3752991Q43559306-AAD0123B-2096-4B41-A70E-515A036A1ADEQ43611095-B50722CA-8888-4C8F-A193-39A7DDC0FBEEQ43636288-D475DA5F-9630-44D8-9E72-EF3468357226Q44747060-C4DBD4C9-D8CE-4224-A395-C189866AB70FQ46954188-1B942929-9411-4034-BCE7-46B0C9802C26Q48107109-50753B5F-FA53-49D6-A831-A82DDBC1624EQ53022774-FAAC1691-04BD-42B7-9F55-40063457754AQ53342430-B96A6C2D-CAE3-4F2D-BEC7-A17B950B12AFQ57193452-12336366-EFB7-4068-96A1-8F5A068AA297Q57496194-A7719A0F-35C5-468D-8B8E-75E90230594AQ57496324-A88781ED-374D-4C35-B5A2-CD9FB156798FQ57496361-03171131-7210-449D-9E80-568F9F404323Q57496366-B863B859-43D3-4E1B-A769-7563ADAA7C49Q57496373-B32814DE-A812-4BD9-BF83-2BB91E96B2A8Q57496379-B995771F-E498-4A0D-A692-BDBE170B99CBQ57496408-BC234187-30D5-47F2-A484-654645B76A41Q57496412-3915F0E2-066C-4E40-9A30-34CE3053D8FEQ57496419-D31BF08D-5B2B-4621-8B3B-607693EAA9AAQ57496439-88714CFF-7F0A-4D32-A39C-12FA6DFA0969Q89694442-6DEEF716-F99F-4DB3-8EB7-1C994B315DAE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Martin Landray
@ast
Martin Landray
@en
Martin Landray
@es
Martin Landray
@nl
Martin Landray
@sl
type
label
Martin Landray
@ast
Martin Landray
@en
Martin Landray
@es
Martin Landray
@nl
Martin Landray
@sl
prefLabel
Martin Landray
@ast
Martin Landray
@en
Martin Landray
@es
Martin Landray
@nl
Martin Landray
@sl
P106
P1153
7004475762
P21
P31
P496
0000-0001-6646-827X